Free antiretrovirals as a key tool against the HIV pandemic: A systematic review
HIV Medicine · 2025
DOI: 10.1111/hiv.70051 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HIV Medicine, 2025. Verfasst von Melissa Doutre und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: HIV Infections, Anti-Retroviral Agents, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Objectives Access to antiretroviral (ARV) drugs remains a critical challenge in achieving the WHO/UNAIDS 95‐95‐95 targets, with medication costs representing a substantial barrier. This systematic review evaluates the effect of free ARVs, without out‐of‐pocket cost to the patient, on the HIV cascade of care: the use of ARV therapy, viral suppression and the use of prophylaxis (PrEP).
Methods
The following databases were searched for publications between 1 January 1996 and 10 July 2024: MEDLINE, Embase, CINAHL, CNKI, Global Index Medicus, the Web of Science, the SciELO Citation Index and grey literature. Publications were eligible if they included people living with or at risk of HIV and compared free access to ARVs with out‐of‐pocket fees. Reviewers screened publications that focused on the outcomes: being on therapy, being virally suppressed and being on PrEP. The National Heart, Lung and Blood Institute (NHLBI) and Joanna Briggs Institute (JBI) Quality Assessment Tools were used to assess publication quality.
Results
A total of 34164 documents were identified, and 407 full‐text manuscripts were reviewed. A total of 22 publications met the inclusion criteria. In six of the seven publications reporting on being on therapy, providing free ARVs increased the number of people who received treatment. All four publications reporting on viral suppression showed improvement with free access. Additionally, both publications reporting on PrEP use showed increased utilization with free access.
Conclusions
The review offers valuable insights for countries considering implementing free ARV programmes. It suggests that expanding access to free ARVs helps achieve the global HIV targets and improve health outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
- Pharmacy Department, McGill University Health Centre, Montreal, Quebec, Canada.
- Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
- Health Library, University of Montreal, Montreal, Quebec, Canada.
ORCID-Profile: Amy Bergeron, Benoît Lemire
Zitieren
APA
Doutre, M., Godin, M. P., Dmitriev, I., Pena-Gralle, A. P., Bergeron, A., Blais, L., & Lemire, B. (2025). Free antiretrovirals as a key tool against the HIV pandemic: A systematic review. HIV Medicine. https://doi.org/10.1111/hiv.70051
Vancouver
Doutre M, Godin MP, Dmitriev I, Pena-Gralle AP, Bergeron A, Blais L, et al. Free antiretrovirals as a key tool against the HIV pandemic: A systematic review. HIV Medicine. 2025. doi:10.1111/hiv.70051
BibTeX
@article{Doutre2025,
author = {Doutre, Melissa and Godin, Marie-Pier and Dmitriev, Iliya and Pena-Gralle, Ana Paula and Bergeron, Amy and Blais, Lucie and Lemire, Benoît},
title = {Free antiretrovirals as a key tool against the HIV pandemic: A systematic review},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70051}
}
EUVIMED